Skip to main content

Table 2 Summary of chemotherapy regimens in combination with the HER2-targeted drugs

From: Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment

Group (A)

first-line

N = 3

second-line

N = 16

third-line

N = 9

four-line

N = 5

Combined treatment

CPT-11

2

CPT-11

13

CPT-11

7

CPT-11

3

S1

1

XELOX

1

XELOX

1

CPT-11 + S1

1

  

XELIRI

1

Xeloda

1

SOX

1

  

Xeloda

1

    
  1. CPT-11 Irinotecan, S1 Tegafur, XELOX capecitabine plus oxaliplatin, XELIRI capecitabine plus irinotecan, SOX Tegafur plus oxaliplatin
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us